0001855485-24-000004.txt : 20240321 0001855485-24-000004.hdr.sgml : 20240321 20240320174833 ACCESSION NUMBER: 0001855485-24-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240320 EFFECTIVENESS DATE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Calidi Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001855485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 862967193 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-508166 FILM NUMBER: 24768776 BUSINESS ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-794-9600 MAIL ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: First Light Acquisition Group, Inc. DATE OF NAME CHANGE: 20210406 D 1 primary_doc.xml X0708 D LIVE 0001855485 Calidi Biotherapeutics, Inc. 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA CALIFORNIA 92121 858-794-9600 DELAWARE First Light Acquisition Group, Inc. Corporation true 2021 Allan Camaisa 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Director Andrew Jackson 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Boris Minev 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Wendy Pizarro 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Alan R. Stewart 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director Scott Leftwich 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director George Ng 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director James A. Schoeneck 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director David LaPre 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director Biotechnology Decline to Disclose 06b false 2024-03-08 false true true true true Convertible promissory note and underlying equity upon conversion of convertible promissory note false 0 3500000 3500000 0 Represents an aggregate principal amount of $3,500,000 of two convertible promissory notes convertible into equity securities of the issuer. false 1 0 0 0 false Calidi Biotherapeutics, Inc. /s/ Andrew Jackson Andrew Jackson Chief Financial Officer 2024-03-20